Verastem starts dosing in all three VS-7375 registration trials, secures added $75M financing
The company reported Q2 2026 results alongside new KRAS G12D trial progress and a royalty deal with Oberland Capital that extends its projected cash runway.
Verastem Oncology said between June 16 and July 28 it dosed the first patients in each of its three TARGET-D registration-directed Phase 2 studies for VS-7375, covering colorectal cancer, non-small cell lung cancer, and pancreatic ductal carcinoma.1 The company said it expects to complete enrollment across all three TARGET-D Phase 2 trials by the end of 2026.1 It also plans to meet with the FDA before year-end to discuss designs for Phase 3 pivotal trials in first-line metastatic PDAC, first-line metastatic CRC, and first-line advanced NSCLC1, with enrollment of the first patient in each Phase 3 trial targeted for the first half of 2027.1 Updated clinical data on VS-7375 across the three tumor types is expected in October, the company said.
In earlier trial updates, Verastem reported that in the RAMP 205 study of avutometinib and defactinib combined with chemotherapy in first-line pancreatic cancer, as of a June 5, 2026 data cutoff with median follow-up of 9.8 months, the combination showed a 52% confirmed objective response rate, an 86% overall survival rate, and a 68% progression-free survival rate at six months.1 In LGSOC, updated RAMP 201 Japan data showed a 44% overall response rate and 94% disease control rate across all patients, with response rates of 71% in KRAS-mutated tumors and 22% in KRAS wild-type tumors.1
On financing, Verastem signed a non-dilutive royalty financing agreement with Oberland Capital providing up to $75 million, including $50 million at closing on August 28, 2026, plus up to $25 million contingent on quarterly AVMAPKI FAKZYNJA CO-PACK sales reaching at least $40 million before May 15, 2027.1 The company also received a $15 million milestone payment in July after Secura Bio's cumulative COPIKTRA sales passed $200 million in Q2 2026.1 Verastem ended the quarter with cash, cash equivalents, and investments of $136.4 million1, or $201.4 million on a pro forma basis including the Oberland and Secura amounts.1 The company said this pro forma position, combined with expected product revenue and the future Oberland tranche, gives it sufficient capital to fund operations into the second half of 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.